Live Analyst Rating Changes 2097 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Elmar Kraus
DB
Elmar Kraus
Wall Street Analyst
★★★★★
#4
on 13Foresight · ranked by our own returns
53%
Success Rate
+5.9%
Average Return
8 of 15 calls profitable · +28.8% vs benchmark
📈 Across the calls we could measure, roughly 53% of Elmar Kraus's ratings turned a profit when each position was held for 1 year — averaging +5.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

13 Buy 14 Hold 0 Sell
Elmar's Stock Coverage 25 ratings · 2026-06-23
Company Date Position Consensus Price Target 1-Yr Return
GB:0QW0
arGEN X
May 08, 2026 BUY Strong Buy
-23.0% avg upside
24 analysts
·
GB:0QIU
Novo Nordisk
May 07, 2026 HOLD Hold
+40.1% avg upside
28 analysts
·
PFE
Pfizer
May 06, 2026 BUY Buy
+34.7% avg upside
45 analysts
-3.9%
GB:GSK
GlaxoSmithKline
Apr 29, 2026 HOLD Hold
-2.6% avg upside
25 analysts
·
GB:AZN
AstraZeneca
Apr 29, 2026 BUY Strong Buy
+11.7% avg upside
26 analysts
$16400.00
23.47% Upside
·
CH:NOVN
Novartis AG
Apr 28, 2026 HOLD Buy
-10.8% avg upside
30 analysts
·
CH:ROP
Roche Holding AG
Feb 02, 2026 BUY Strong Buy
+3.5% avg upside
23 analysts
·
ABBV
AbbVie
Nov 04, 2025 HOLD Buy
-2.2% avg upside
43 analysts
$237.00
3.06% Upside
+6.7%
FR:SAN
Sanofi
Oct 24, 2025 BUY Strong Buy
+35.8% avg upside
30 analysts
·
NL:PHIA
Koninklijke Philips N.V.
Jul 29, 2025 HOLD Buy
+30.6% avg upside
20 analysts
·
GILD
Gilead Sciences
Feb 13, 2025 BUY Strong Buy
-5.3% avg upside
66 analysts
$108.00
13.56% Downside
+50.3%
AMGN
Amgen
May 07, 2024 BUY Buy
-12.8% avg upside
57 analysts
$343.00
0.58% Downside
-5.3%
REGN
Regeneron
May 06, 2024 BUY Strong Buy
+26.8% avg upside
57 analysts
$1065.00
73.81% Upside
-41.7%
LLY
Eli Lilly & Co
May 03, 2024 HOLD Buy
-10.5% avg upside
47 analysts
$800.00
27.50% Downside
+12.8%
BMY
Bristol-Myers Squibb
Apr 30, 2024 BUY Buy
+8.2% avg upside
42 analysts
$50.00
8.65% Downside
+19.9%
MRK
Merck & Company
Apr 29, 2024 BUY Strong Buy
+9.7% avg upside
43 analysts
$148.00
28.16% Upside
-33.0%
JNJ
Johnson & Johnson
Apr 18, 2024 BUY Strong Buy
-4.4% avg upside
36 analysts
$176.00
23.84% Downside
+11.5%
BIIB
Biogen
Feb 15, 2024 HOLD Buy
+23.7% avg upside
51 analysts
$236.00
18.22% Upside
-38.5%
PFS
Provident Financial Services
Nov 02, 2023 BUY Strong Buy
+33.6% avg upside
16 analysts
$39.00
69.42% Upside
+32.7%
DE:SHL
Siemens Healthineers AG
Apr 20, 2022 HOLD Buy
+50.9% avg upside
22 analysts
·
GSK
GlaxoSmithKline
Feb 11, 2022 HOLD Hold
-14.2% avg upside
19 analysts
-15.5%
DE:FPE3
Fuchs Petrolub
Aug 24, 2021 BUY Strong Buy
+22.8% avg upside
10 analysts
·
MDT
Medtronic
May 14, 2020 HOLD Buy
+23.6% avg upside
38 analysts
$92.00
16.06% Upside
+36.5%
PHG
Koninklijke Philips
Mar 24, 2020 BUY Strong Buy
+29.7% avg upside
13 analysts
$41.43
53.53% Upside
+57.4%
NVO
Novo Nordisk
May 03, 2018 SELL Hold
+158.8% avg upside
26 analysts
-1.2%
🔒 20 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Elmar Kraus — Frequently Asked Questions
How accurate are Elmar Kraus's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Elmar's ratings were profitable over a one-year hold, with an average return of +5.9% per rating, or +28.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Elmar ranked on 13Foresight?
Elmar Kraus is currently ranked #4 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Elmar cover?
Elmar most recently has ratings on GB:0QW0, GB:0QIU, PFE, GB:GSK, GB:AZN, CH:NOVN, CH:ROP, ABBV, FR:SAN, NL:PHIA, GILD, AMGN and 13 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.